SELECT.

StructurE-unbiased Library for Exploratory disCovery of Targets

“SELECT facilitates groundbreaking discoveries.”

“SELECT is not just a platform—it’s a catalyst for innovation. By bridging chemistry and biology, we unlock new therapeutic possibilities and empower researchers to explore uncharted territories in drug discovery.”

Our Mission

The SELECT platform (StructurE-unbiased Library for Exploratory disCovery of Targets) is dedicated to advancing drug discovery by enabling the identification of novel biological targets, chemical tools, and therapeutic compounds. Our mission is to accelerate the development of innovative treatments for viral infections and cancer by leveraging a structurally diverse compound library and cutting-edge screening technologies.

Our History

The SELECT platform builds upon the legacy of Prof. Erik De Clercq’s renowned antiviral screening efforts. It was conceived to centralize and modernize compound management and screening services, transforming decades of expertise into a streamlined, high-impact research engine.

What we offer

Compound Library Management

A centralized repository of structurally diverse compounds.

Antiviral & Anticancer Screening

Phenotypic screening using relevant disease models.

Target Deconvolution

Advanced tools including CRISPR and cell painting to uncover mechanisms of action.

Data Integration & AI Readiness

Comprehensive data management systems ready for future AI-driven drug design.

Collaboration Framework: Protected by a Standard MTA

All compound submissions to the SELECT platform are governed by a standard Material Transfer Agreement (MTA), ensuring a transparent and secure collaboration between KU Leuven and contributing chemists.

Key points of the agreement:

  • Compounds are received solely for non-commercial research.
  • KU Leuven will not modify, redistribute, or use the compounds outside the agreed scope without prior consent.
  • Providers retain full ownership of their compounds. 
  • Publications will be co-authored and subject to pre-publication review.
  • Intellectual property arising from the collaboration will be shared equally, and any patent filings or exploitation will require mutual agreement.